Explore the options for EGFR-targeted therapy in the treatment of patients with glioblastoma (GBM). Watch these expert perspectives for a focused look at EGFR in GBM. The faculty summarize their presentations from the live meeting and provide their insights and commentary.
0.5 AMA PRA Category 1 Credit™
Dec 21, 2017
Dec 21, 2018
Andrew Lassman, MDColumbia University
New York, New York, United States
David Reardon, MDDana-Farber Cancer Institute
Boston, Massachusetts, United States
John H. Sampson, MD, PhD Duke University
Durham, North Carolina, United States
David Reardon, MD
Molecular classification and the search for targets in GBM
John H. Sampson, MD, PhD
Drilling down on EGFR-targeted therapy
Andrew Lassman, MD
This activity is designed to meet the needs of medical oncologists, neuro-oncologists, and other healthcare professionals involved in the treatment of patients with glioblastoma (GBM).
After successful completion of this educational activity, participants should be able to:
- Evaluate the molecular subgroups that are being incorporated into classification of GBMs
- Assess EGFR testing in GBM and the role of repeat biopsy at the time of progressive disease
- Summarize the different EGFR-targeted strategies being investigated in GBMs
This educational activity is supported by a grant from AbbVie.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
prIME Oncology designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring activity is provided by prIME Oncology.
Method of Participation
Links to the posttest are available on the video player pages.
In order to receive credit, participants must successfully complete the online posttest with 75% or higher.
Disclosure of Relevant Financial Relationships
prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Reardon has disclosed receiving consulting fees and honoraria for promotional speaker’s bureaus from AbbVie, Agenus, Amgen, Bristol-Myers Squibb, Cavion, Celldex Therapeutics, EMD Serono, Genentech/Roche, Inovio, Juno Pharmaceuticals, Merck, Midatech, Momenta Pharmaceuticals, Novartis, Novocure, Oxigene, Regeneron, and Stemline Therapeutics. He has also disclosed independent contracting for Acerta Pharm, Agenus, Celldex Therapeutics, EMD Serono, Incyte, Inovio, Midatech, and Tragara. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Lassman has disclosed receiving consulting fees from AbbVie, AstraZeneca, Cortice, Kadmon, Novocure, Sapience, and WebMD. He has also disclosed that he has received travel support from Bristol-Myers Squibb and Karyopharm. Dr Lassman has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Sampson has disclosed receiving consulting fees from Bristol-Myers Squibb, Immunomix Therapeutics, and Medicenna. He also disclosed equity and licensed intellectual property (IP) from Annias Immunotherapeutics and Istari Oncology. He also disclosed licensed IP and royalties from Celldex, equity and optioned IP from Neuronium, and sublicense of IP from Annias and Immunomix Therapeutics. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of prIME Oncology have disclosed:
- Janice Galleshaw, MD (medical director content reviewer/planner) – no relevant financial relationships
- Briana Betz, PhD (scientific content reviewer/planner) – no relevant financial relationships
- Heather Tomlinson, ELS (editorial content reviewer) – no relevant financial relationships
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.